Loading...
•
Dec 31, 2021
Balchem Q4 2021 Earnings Report
Balchem reported record Q4 sales and solid growth across all segments.
Key Takeaways
Balchem Corporation reported record fourth-quarter sales of $213.1 million and net earnings of $24.9 million, with GAAP EPS of $0.76 and adjusted EPS of $0.85. The company experienced growth in all three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.
Record net sales of $213.1 million, an increase of 17.9% year-over-year.
Record adjusted EBITDA of $45.6 million, up 4.7% from the prior year.
GAAP net earnings increased by 12.6% year-over-year to $24.9 million, resulting in GAAP earnings per share of $0.76.
Adjusted net earnings increased by 3.5% year-over-year to $27.8 million, with adjusted earnings per share of $0.85.
Balchem
Balchem
Balchem Revenue by Segment
Revenue by Segment
Human Nutrition & Health Revenue
CapyFin.comAnimal Nutrition & Health Revenue
CapyFin.comSpecialty Products Revenue
CapyFin.com Forward Guidance
Balchem anticipates another growth year, navigating macroeconomic challenges through strategic sourcing and pricing adjustments.
Positive Outlook
- Healthy overall demand for product offerings.
- Implementation of alternate sourcing strategies.
- Active price increases to combat inflation.
- Well-positioned within served markets.
- Strong cash flow generation.
Challenges Ahead
- Challenging macroeconomic environment.
- Global supply chain disruptions.
- Significant input cost inflation.
- Tight labor market.
- Inflationary pressures impacting margins.
Revenue & Expenses
Visualization of income flow from segment revenue to net income